The DOI matches its Crossref record; 322 of the 322 references it cites were found in a registry or an index.
Structure, heterogeneity and developability assessment of therapeutic antibodies
Open accessAbstract
Increasing attention has been paid to developability assessment with the understanding that thorough evaluation of monoclonal antibody lead candidates at an early stage can avoid delays during late-stage development. The concept of developability is based on the knowledge gained from the successful development of approximately 80 marketed antibody and Fc-fusion protein drug products and from the lessons learned from many failed development programs over the last three decades. Here, we reviewed antibody quality attributes that are critical to development and traditional and state-of-the-art analytical methods to monitor those attributes. Based on our collective experiences, a practical workflow is proposed as a best practice for developability assessment including in silico evaluation, extended characterization and forced degradation using appropriate analytical methods that allow characterization with limited material consumption and fast turnaround time.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Niesen, F. H., Berglund, H., & Vedadi, M. (2007) · Nature Protocols · doi:10.1038/nprot.2007.321 · Cited by 2,408
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
Effects of protein aggregates: An immunologic perspective
Rosenberg, A. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080359 · Cited by 1,355
Parekh, R. B., Dwek, R. A., Sutton, B. J., Fernandes, D. L., Leung, A., Stanworth, D., Rademacher, T. W., Mizuochi, T., Taniguchi, T., Matsuta, K., et al. (1985) · Nature · doi:10.1038/316452a0 · Cited by 1,170
Strategies and challenges for the next generation of therapeutic antibodies
Beck, A., Wurch, T., Bailly, C., & Corvaia, N. (2010) · Nature Reviews Immunology · doi:10.1038/nri2747 · Cited by 847
Self-citationNext generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Harding, F. A., Stickler, M. M., Razo, J., & DuBridge, R. (2010) · mAbs · doi:10.4161/mabs.2.3.11641 · Cited by 737
Biophysical properties of the clinical-stage antibody landscape
Jain, T., Sun, T., Durand, S., Hall, A., Houston, N. R., Nett, J. H., Sharkey, B., Bobrowicz, B., Caffry, I., Yu, Y., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616408114 · Cited by 629 · cited 1×
“Besides aggregation, mAbs with lower thermal stability have been shown to have lower expression.(73,207) Thermal stability has been commonly measured by differential scanning calorimetry (DSC).”
BackgroundSelf-citationDesign of therapeutic proteins with enhanced stability
Chennamsetty, N., Voynov, V., Kayser, V., Helk, B., & Trout, B. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904191106 · Cited by 598
Analysis of Protein Stability and Ligand Interactions by Thermal Shift Assay
Huynh, K., & Partch, C. L. (2015) · Current Protocols in Protein Science · doi:10.1002/0471140864.ps2809s79 · Cited by 575
Yamane‐Ohnuki, N., Kinoshita, S., Inoue‐Urakubo, M., Kusunoki, M., Iida, S., Nakano, R., Wakitani, M., Niwa, R., Sakurada, M., Uchida, K., et al. (2004) · Biotechnology and Bioengineering · doi:10.1002/bit.20151 · Cited by 572
Terminal sugars of Fc glycans influence antibody effector functions of IgGs
Raju, T. S. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.007 · Cited by 521
Identification of multiple sources of charge heterogeneity in a recombinant antibody
Harris, R. J., Kabakoff, B., Macchi, F. D., Shen, F. J., Kwong, M., Andya, J. D., Shire, S. J., Bjork, N., Totpal, K., & Chen, A. B. (2001) · Journal of Chromatography B: Biomedical Sciences and Applications · doi:10.1016/s0378-4347(00)00548-x · Cited by 500
Acceptable changes in quality attributes of glycosylated biopharmaceuticals
Schiestl, M., Stangler, T., Torella, C., Čepeljnik, T., Toll, H., & Grau, R. (2011) · Nature Biotechnology · doi:10.1038/nbt.1839 · Cited by 473
Goetze, A. M., Liu, Y. D., Zhang, Z., Shah, B., Lee, E., Bondarenko, P. V., & Flynn, G. C. (2011) · Glycobiology · doi:10.1093/glycob/cwr027 · Cited by 467
Raju, T. S., Briggs, J. B., Borge, S. M., & Jones, A. J. S. (2000) · Glycobiology · doi:10.1093/glycob/10.5.477 · Cited by 452
Ali, S., Hassan, M., Islam, A., & Ahmad, F. (2014) · Current Protein & Peptide Science · doi:10.2174/1389203715666140327114232 · Cited by 447
Liu, J., Nguyen, M. D. H., Andya, J. D., & Shire, S. J. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20347 · Cited by 436
Liu, L. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24444 · Cited by 428 · cited 3×
“C-terminal Lys has no impact on mAb potency77,78 PK, PD or immunogenicity.78 However, removal of C-terminal Lys showed optimal C1q binding and CDC.79 C-terminal Lys is rapidly removed during circulation,80 explaining its absence from endogenous IgGs.80 Removal of the codon for C-terminal Lys can eliminate this heterog…”
BackgroundKhawli, L. A., Goswami, S., Hutchinson, R., Kwong, Z. W., Yang, J., Wang, X., Yao, Z., Sreedhara, A., Cano, T., Tesar, D. B., et al. (2010) · mAbs · doi:10.4161/mabs.2.6.13333 · Cited by 419
Shaken, Not Stirred: Mechanical Stress Testing of an IgG1 Antibody
Kiese, S., Papppenberger, A., Friess, W., & Mahler, H.-C. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21328 · Cited by 397
Post-translational Modifications Differentially Affect IgG1 Conformation and Receptor Binding
Houde, D., Peng, Y., Berkowitz, S. A., & Engen, J. R. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900540-mcp200 · Cited by 393
Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
Liu, L. (2018) · Protein & Cell · doi:10.1007/s13238-017-0408-4 · Cited by 390
Kanda, Y., Yamada, T., Mori, K., Okazaki, A., Inoue, M., Kitajima-Miyama, K., Kuni-Kamochi, R., Nakano, R., Yano, K., Kakita, S., et al. (2007) · Glycobiology · doi:10.1093/glycob/cwl057 · Cited by 372
Velev, O. D., Kaler, E. W., & Lenhoff, A. M. (1998) · Biophysical Journal · doi:10.1016/s0006-3495(98)77713-6 · Cited by 348
Connolly, B. D., Petry, C., Yadav, S., Demeule, B., Ciaccio, N., Moore, J. M. R., Shire, S. J., & Gokarn, Y. R. (2012) · Biophysical Journal · doi:10.1016/j.bpj.2012.04.047 · Cited by 340
Singh, S. K., Afonina, N., Awwad, M., Bechtold-Peters, K., Blue, J. T., Chou, D., Cromwell, M., Krause, H.-J., Mahler, H.-C., Meyer, B. K., et al. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22097 · Cited by 334
Mimura, Y., Church, S., Ghirlando, R., Ashton, P. R., Dong, S., Goodall, M., Lund, J., & Jefferis, R. (2000) · Molecular Immunology · doi:10.1016/s0161-5890(00)00105-x · Cited by 329
Analysis of immunoglobulin glycosylation by LC‐ESI‐MS of glycopeptides and oligosaccharides
Stadlmann, J., Pabst, M., Kolarich, D., Kunert, R., & Altmann, F. (2008) · PROTEOMICS · doi:10.1002/pmic.200700968 · Cited by 328
Classification and Characterization of Therapeutic Antibody Aggregates
Joubert, M. K., Luo, Q., Nashed-Samuel, Y., Wypych, J., & Narhi, L. O. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.160457 · Cited by 316
Induction and analysis of aggregates in a liquid IgG1-antibody formulation
Mahler, H.-C., Müller, R., Frieβ, W., Delille, A., & Matheus, S. (2005) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.12.004 · Cited by 309
Kanai, S., Liu, J., Patapoff, T. W., & Shire, S. J. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21322 · Cited by 304
Advances in the assessment and control of the effector functions of therapeutic antibodies
Jiang, X.-R., Song, A., Bergelson, S., Arroll, T., Parekh, B., May, K., Chung, S., Strouse, R., Mire-Sluis, A., & Schenerman, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3365 · Cited by 299
Qian, J., Liu, T., Yang, L., Daus, A., Crowley, R., & Zhou, Q. (2007) · Analytical Biochemistry · doi:10.1016/j.ab.2007.01.023 · Cited by 291
Yadav, S., Laue, T. M., Kalonia, D. S., Singh, S. N., & Shire, S. J. (2012) · Molecular Pharmaceutics · doi:10.1021/mp200566k · Cited by 280
Current progress in innovative engineered antibodies
Strohl, W. R. (2018) · Protein & Cell · doi:10.1007/s13238-017-0457-8 · Cited by 279
In Vivo Deamidation Characterization of Monoclonal Antibody by LC/MS/MS
Huang, L., Lu, J., Wroblewski, V. J., Beals, J. M., & Riggin, R. M. (2005) · Analytical Chemistry · doi:10.1021/ac0494174 · Cited by 266
Chelius, D., Rehder, D. S., & Bondarenko, P. V. (2005) · Analytical Chemistry · doi:10.1021/ac050672d · Cited by 263
Antioxidants for Prevention of Methionine Oxidation in Recombinant Monoclonal Antibody HER2
Lam, X. M., Yang, J. Y., & Cleland, J. L. (1997) · Journal of Pharmaceutical Sciences · doi:10.1021/js970143s · Cited by 263
Structure and Stability Changes of Human IgG1 Fc as a Consequence of Methionine Oxidation
Liu, D., Ren, D., Huang, H., Dankberg, J., Rosenfeld, R., Cocco, M. J., Li, L., Brems, D. N., & Remmele, R. L. (2008) · Biochemistry · doi:10.1021/bi702238b · Cited by 261
Self-citationForced degradation of recombinant monoclonal antibodies: A practical guide
Nowak, C., K. Cheung, J., M. Dellatore, S., Katiyar, A., Bhat, R., Sun, J., Ponniah, G., Neill, A., Mason, B., Beck, A., et al. (2017) · mAbs · doi:10.1080/19420862.2017.1368602 · Cited by 260
Self-citationImpact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies
Wang, W., Vlasak, J., Li, Y., Pristatsky, P., Fang, Y., Pittman, T., Roman, J., Wang, Y., Prueksaritanont, T., & Ionescu, R. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2010.12.009 · Cited by 257
Structural properties of monoclonal antibody aggregates induced by freeze–thawing and thermal stress
Hawe, A., Kasper, J. C., Friess, W., & Jiskoot, W. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.06.001 · Cited by 255
Factors Affecting the Viscosity in High Concentration Solutions of Different Monoclonal Antibodies
Yadav, S., Shire, S. J., & Kalonia, D. S. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22190 · Cited by 255
Sharma, V. K., Patapoff, T. W., Kabakoff, B., Pai, S., Hilario, E., Zhang, B., Li, C., Borisov, O., Kelley, R. F., Chorny, I., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421779112 · Cited by 254
Vlasak, J., Bussat, M. C., Wang, S., Wagner-Rousset, E., Schaefer, M., Klinguer-Hamour, C., Kirchmeier, M., Corvaïa, N., Ionescu, R., & Beck, A. (2009) · Analytical Biochemistry · doi:10.1016/j.ab.2009.05.043 · Cited by 252
Self-citationSpecific interactions in high concentration antibody solutions resulting in high viscosity
Yadav, S., Liu, J., Shire, S. J., & Kalonia, D. S. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21898 · Cited by 252
Tiller, K. E., & Tessier, P. M. (2015) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071114-040733 · Cited by 251
A strategy for risk mitigation of antibodies with fast clearance
Hötzel, I., Theil, F.-P., Bernstein, L. J., Prabhu, S., Deng, R., Quintana, L., Lutman, J., Sibia, R., Chan, P., Bumbaca, D., et al. (2012) · mAbs · doi:10.4161/mabs.22189 · Cited by 245
Is any measurement method optimal for all aggregate sizes and types?
Philo, J. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080365 · Cited by 245
Kaplon, H., & Reichert, J. M. (2018) · mAbs · doi:10.1080/19420862.2018.1415671 · Cited by 244
Developability Assessment During the Selection of Novel Therapeutic Antibodies
Jarasch, A., Koll, H., Regula, J. T., Bader, M., Papadimitriou, A., & Kettenberger, H. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24430 · Cited by 242
Role of Oligosaccharide Residues of IgG1-Fc in FcγRIIb Binding
Mimura, Y., Sondermann, P., Ghirlando, R., Lund, J., Young, S. P., Goodall, M., & Jefferis, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107478200 · Cited by 236
Impact of methionine oxidation on the binding of human IgG1 to FcRn and Fcγ receptors
Bertolotti-Ciarlet, A., Wang, W., Lownes, R., Pristatsky, P., Fang, Y., McKelvey, T., Li, Y., Li, Y., Drummond, J., Prueksaritanont, T., et al. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.02.002 · Cited by 235
Goyon, A., Excoffier, M., Janin-Bussat, M.-C., Bobaly, B., Fekete, S., Guillarme, D., & Beck, A. (2017) · Journal of Chromatography B · doi:10.1016/j.jchromb.2017.09.033 · Cited by 227
Self-citationJunttila, T. T., Parsons, K., Olsson, C., Lu, Y., Xin, Y., Theriault, J., Crocker, L., Pabonan, O., Baginski, T., Meng, G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3704 · Cited by 221
Rapid Measurement of Protein Osmotic Second Virial Coefficients by Self-Interaction Chromatography
Tessier, P. M., Lenhoff, A. M., & Sandler, S. I. (2002) · Biophysical Journal · doi:10.1016/s0006-3495(02)75513-6 · Cited by 217
Lavinder, J. J., Hari, S. B., Sullivan, B. J., & Magliery, T. J. (2009) · Journal of the American Chemical Society · doi:10.1021/ja8049063 · Cited by 213
Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease
WEST, R. L., ZELINKOVA, Z., WOLBINK, G. J., KUIPERS, E. J., STOKKERS, P. C. F., & VAN DER WOUDE, C. J. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03828.x · Cited by 213
Developability Index: A Rapid In Silico Tool for the Screening of Antibody Aggregation Propensity
Lauer, T. M., Agrawal, N. J., Chennamsetty, N., Egodage, K., Helk, B., & Trout, B. L. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22758 · Cited by 207
Quan, C., Alcala, E., Petkovska, I., Matthews, D., Canova-Davis, E., Taticek, R., & Ma, S. (2008) · Analytical Biochemistry · doi:10.1016/j.ab.2007.09.027 · Cited by 206
Yamaguchi, Y., Nishimura, M., Nagano, M., Yagi, H., Sasakawa, H., Uchida, K., Shitara, K., & Kato, K. (2006) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2005.10.002 · Cited by 204
Yu, M., Brown, D., Reed, C., Chung, S., Lutman, J., Stefanich, E., Wong, A., Stephan, J.-P., & Bayer, R. (2012) · mAbs · doi:10.4161/mabs.20737 · Cited by 203 · cited 1×
“High mannose has been shown to cause shorter in vivo half-life(185-191) and enhanced antibody-dependent cell-meditated cytotoxicity (ADCC) due to the lack of core-fucose.(187,190,191) Additionally,”
BackgroundMethionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn
Pan, H., Chen, K., Chu, L., Kinderman, F., Apostol, I., & Huang, G. (2009) · Protein Science · doi:10.1002/pro.45 · Cited by 203
Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics
Schoch, A., Kettenberger, H., Mundigl, O., Winter, G., Engert, J., Heinrich, J., & Emrich, T. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408766112 · Cited by 202
Cacia, J., Keck, R., Presta, L. G., & Frenz, J. (1996) · Biochemistry · doi:10.1021/bi951526c · Cited by 202
Prediction of aggregation prone regions of therapeutic proteins
Chennamsetty, N., Voynov, V., Kayser, V., Helk, B., & Trout, B. L. (2010) · The Journal of Physical Chemistry B · doi:10.1021/jp911706q · Cited by 200
Formation of Pyroglutamic Acid from N-Terminal Glutamic Acid in Immunoglobulin Gamma Antibodies
Chelius, D., Jing, K., Lueras, A., Rehder, D. S., Dillon, T. M., Vizel, A., Rajan, R. S., Li, T., Treuheit, M. J., & Bondarenko, P. V. (2006) · Analytical Chemistry · doi:10.1021/ac051827k · Cited by 200
Kueltzo, L. A., Wang, W. E. I., Randolph, T. W., & Carpenter, J. F. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21110 · Cited by 200
Chemical Modifications in Therapeutic Protein Aggregates Generated under Different Stress Conditions
Luo, Q., Joubert, M. K., Stevenson, R., Ketchem, R. R., Narhi, L. O., & Wypych, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.160440 · Cited by 199
Harris, R. J. (1995) · Journal of Chromatography A · doi:10.1016/0021-9673(94)01255-d · Cited by 197
A critical review of methods for size characterization of non-particulate protein aggregates
Philo, J. (2009) · Current Pharmaceutical Biotechnology · doi:10.2174/138920109788488815 · Cited by 196
Wright, A., & Morrison, S. L. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.3.1087 · Cited by 192
High throughput thermostability screening of monoclonal antibody formulations
He, F., Hogan, S., Latypov, R. F., Narhi, L. O., & Razinkov, V. I. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21955 · Cited by 192
Chumsae, C., Gaza-Bulseco, G., Sun, J., & Liu, H. (2007) · Journal of Chromatography B · doi:10.1016/j.jchromb.2006.11.050 · Cited by 191
Self-citationAndya, J. D., Maa, Y.-F., Costantino, H. R., Nguyen, P.-A., Dasovich, N., Sweeney, T. D., Hsu, C. C., & Shire, S. J. (1999) · Pharmaceutical Research · doi:10.1023/a:1018805232453 · Cited by 190
Dillon, T. M., Bondarenko, P. V., Rehder, D. S., Pipes, G. D., Kleemann, G. R., & Ricci, M. S. (2006) · Journal of Chromatography A · doi:10.1016/j.chroma.2006.01.016 · Cited by 189
Non-enzymatic hinge region fragmentation of antibodies in solution
Cordoba, A. J., Shyong, B.-J., Breen, D., & Harris, R. J. (2005) · Journal of Chromatography B · doi:10.1016/j.jchromb.2004.12.033 · Cited by 188
High-concentration protein formulations: How high is high?
Garidel, P., Kuhn, A. B., Schäfer, L. V., Karow-Zwick, A. R., & Blech, M. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.06.029 · Cited by 187 · cited 1×
“Solubility is an important developability parameter for mAbs,(211,212) especially in consideration of the industry trend towards higher concentration formulations (100 mg/mL and above).(213) MAbs must remain soluble throughout processing, storage and administration.”
BackgroundDudgeon, K., Rouet, R., Kokmeijer, I., Schofield, P., Stolp, J., Langley, D., Stock, D., & Christ, D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202866109 · Cited by 185
Ayoub, D., Jabs, W., Resemann, A., Evers, W., Evans, C., Main, L., Baessmann, C., Wagner-Rousset, E., Suckau, D., & Beck, A. (2013) · mAbs · doi:10.4161/mabs.25423 · Cited by 184
Self-citationZhou, Q., Shankara, S., Roy, A., Qiu, H., Estes, S., McVie‐Wylie, A., Culm‐Merdek, K., Park, A., Pan, C., & Edmunds, T. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21598 · Cited by 184
Structure-based engineering of a monoclonal antibody for improved solubility
Wu, S.-J., Luo, J., O'Neil, K. T., Kang, J., Lacy, E. R., Canziani, G., Baker, A., Huang, M., Tang, Q. M., Raju, T. S., et al. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq037 · Cited by 183
Xu, Y., Roach, W., Sun, T., Jain, T., Prinz, B., Yu, T.-Y., Torrey, J., Thomas, J., Bobrowicz, P., Vasquez, M., et al. (2013) · Protein Engineering Design and Selection · doi:10.1093/protein/gzt047 · Cited by 178
Self-citationFornelli, L., Ayoub, D., Aizikov, K., Beck, A., & Tsybin, Y. O. (2014) · Analytical Chemistry · doi:10.1021/ac4036857 · Cited by 177
Self-citationN-terminal Glutamate to Pyroglutamate Conversion in Vivo for Human IgG2 Antibodies
Liu, Y. D., Goetze, A. M., Bass, R. B., & Flynn, G. C. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.185041 · Cited by 175
Yan, B., Steen, S., Hambly, D., Valliere-Douglass, J., Bos, T. V., Smallwood, S., Yates, Z., Arroll, T., Han, Y., Gadgil, H., et al. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21655 · Cited by 174
Yadav, S., Shire, S. J., & Kalonia, D. S. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22831 · Cited by 174
Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies
Kayser, V., Chennamsetty, N., Voynov, V., Forrer, K., Helk, B., & Trout, B. L. (2011) · Biotechnology Journal · doi:10.1002/biot.201000091 · Cited by 172
Wei, Z., Feng, J., Lin, H.-Y., Mullapudi, S., Bishop, E., Tous, G. I., Casas-Finet, J., Hakki, F., Strouse, R., & Schenerman, M. A. (2007) · Analytical Chemistry · doi:10.1021/ac062311j · Cited by 166
Monoclonal Antibody Self-Association, Cluster Formation, and Rheology at High Concentrations
Lilyestrom, W. G., Yadav, S., Shire, S. J., & Scherer, T. (2013) · The Journal of Physical Chemistry B · doi:10.1021/jp4008152 · Cited by 163
Measuring and Increasing Protein Solubility
Trevino, S. R., Scholtz, J. M., & Pace, C. N. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21327 · Cited by 163
Wright, A., Tao, M. H., Kabat, E. A., & Morrison, S. L. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb07819.x · Cited by 162
Sydow, J. F., Lipsmeier, F., Larraillet, V., Hilger, M., Mautz, B., Mølhøj, M., Kuentzer, J., Klostermann, S., Schoch, J., Voelger, H. R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100736 · Cited by 161
Viscosity Control of Protein Solution by Small Solutes: A Review
Hong, T., Iwashita, K., & Shiraki, K. (2017) · Current Protein and Peptide Science · doi:10.2174/1389203719666171213114919 · Cited by 161
Dick, L. W., Qiu, D., Mahon, D., Adamo, M., & Cheng, K. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21855 · Cited by 159
Brader, M. L., Estey, T., Bai, S., Alston, R. W., Lucas, K. K., Lantz, S. R., Landsman, P., & Maloney, K. M. (2015) · Molecular Pharmaceutics · doi:10.1021/mp400666b · Cited by 159
Wright, A., & Morrison, S. L. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.7.3393 · Cited by 158
Zhang, A., Singh, S. K., Shirts, M. R., Kumar, S., & Fernández, E. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0538-y · Cited by 156
Aggregation-Prone Motifs in Human Immunoglobulin G
Chennamsetty, N., Helk, B., Voynov, V., Kayser, V., & Trout, B. L. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.06.028 · Cited by 156
He, F., Becker, G. W., Litowski, J. R., et al. (2009) · Analytical Biochemistry · doi:10.1016/j.ab.2009.12.003 · Cited by 153
Cohen, S. L., Price, C. E., & Vlasak, J. (2007) · Journal of the American Chemical Society · doi:10.1021/ja0705994 · Cited by 150
Rapid and accurate in silico solubility screening of a monoclonal antibody library
Sormanni, P., Amery, L., Ekizoglou, S., Vendruscolo, M., & Popovic, B. (2017) · Scientific Reports · doi:10.1038/s41598-017-07800-w · Cited by 148
Lyubarskaya, Y. V., Houde, D. J., Woodard, J. P., Murphy, D., & Mhatre, R. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2005.10.003 · Cited by 147
Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies
Schlothauer, T., Rueger, P., Stracke, J. O., Hertenberger, H., Fingas, F., Kling, L., Emrich, T., Drabner, G., Seeber, S., Auer, J., et al. (2013) · mAbs · doi:10.4161/mabs.24981 · Cited by 146
Identification of Sites of Degradation in a Therapeutic Monoclonal Antibody by Peptide Mapping
Kroon, D. J., Baldwin-Ferro, A., & Lalan, P. (1992) · Pharmaceutical Research · doi:10.1023/a:1015894409623 · Cited by 145
Datta‐Mannan, A., Thangaraju, A., Leung, D., Tang, Y., Witcher, D. R., Lu, J., & Wroblewski, V. J. (2015) · mAbs · doi:10.1080/19420862.2015.1016696 · Cited by 144
Haverick, M. A., Mengisen, S., Shameem, M., & Ambrogelly, A. (2014) · mAbs · doi:10.4161/mabs.28693 · Cited by 144
Impact of variable domain glycosylation on antibody clearance: An LC/MS characterization
Huang, L., Biolsi, S., Bales, K. R., & Kuchibhotla, U. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2005.11.012 · Cited by 144
Agrawal, N. J., Kumar, S., Wang, X., Helk, B., Singh, S. K., & Trout, B. L. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22705 · Cited by 144
A new tool for monoclonal antibody analysis
An, Y., Zhang, Y., Mueller, H.-M., Shameem, M., & Chen, X. (2014) · mAbs · doi:10.4161/mabs.28762 · Cited by 144
Effect of Ions on Agitation- and Temperature-Induced Aggregation Reactions of Antibodies
Fesinmeyer, R. M., Hogan, S., Saluja, A., Brych, S. R., Kras, E., Narhi, L. O., Brems, D. N., & Gokarn, Y. R. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9792-z · Cited by 141
Liu, Y., Caffry, I., Wu, J., Geng, S. B., Jain, T. S., Sun, T., Reid, F., Cao, Y., Estep, P., Yu, Y., et al. (2013) · mAbs · doi:10.4161/mabs.27431 · Cited by 141
Self-citationHeterogeneity of recombinant antibodies: linking structure to function.
Harris, R. (2005) · PubMed · Cited by 141
Determination of the Origin of Charge Heterogeneity in a Murine Monoclonal Antibody
Perkins, M. D., Theiler, R., Lunte, S. M., & Jeschke, M. (2000) · Pharmaceutical Research · doi:10.1023/a:1026461830617 · Cited by 140
Dick, L. W., Kim, C., Qiu, D., & Cheng, K. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.21260 · Cited by 140
Neergaard, M. S., Kalonia, D. S., Parshad, H., Nielsen, A. D., Møller, E. H., & van de Weert, M. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.04.019 · Cited by 139
Wallick, S. C., Kabat, E. A., & Morrison, S. L. (1988) · The Journal of Experimental Medicine · doi:10.1084/jem.168.3.1099 · Cited by 138
Telikepalli, S. N., Kumru, O. S., Kalonia, C. K., Esfandiary, R., Joshi, S. B., Middaugh, C. R., & Volkin, D. B. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23839 · Cited by 137
Galactosylation variations in marketed therapeutic antibodies
Raju, T. S., & Jordan, R. E. (2012) · mAbs · doi:10.4161/mabs.19868 · Cited by 136
Naturally occurring glycan forms of human immunoglobulins G1 and G2
Flynn, G. C., Chen, X., Liu, D., Shah, B., & Zhang, Z. (2010) · Molecular Immunology · doi:10.1016/j.molimm.2010.04.006 · Cited by 135
Self-citationDobson, C., Devine, P. W. A., Phillips, J. J., Higazi, D. R., Lloyd, C., Popovic, B., Arnold, J., Buchanan, A. G., Lewis, A. R., Goodman, J., et al. (2016) · Scientific Reports · doi:10.1038/srep38644 · Cited by 134
Glycosylation of therapeutic proteins in different production systems
Werner, R. G., Kopp, K., & Schlueter, M. (2007) · Acta Paediatrica · doi:10.1111/j.1651-2227.2007.00199.x · Cited by 133
Li, L., Kumar, S., Buck, P. M., Burns, C., Lavoie, J., Singh, S. K., Warne, N. W., Nichols, P., Luksha, N., & Boardman, D. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1409-0 · Cited by 132
Computational tool for the early screening of monoclonal antibodies for their viscosities
Agrawal, N. J., Helk, B., Kumar, S., Mody, N., Sathish, H. A., Samra, H. S., Buck, P. M., Li, L., & Trout, B. L. (2015) · mAbs · doi:10.1080/19420862.2015.1099773 · Cited by 132
Chaderjian, W. B., Chin, E. T., Harris, R. J., & Etcheverry, T. (2005) · Biotechnology Progress · doi:10.1021/bp0497029 · Cited by 131
Wakankar, A. A., Borchardt, R. T., Eigenbrot, C. W., et al. (2007) · Biochemistry · doi:10.1021/bi061500t · Cited by 128
van Bueren, J. J. L., Rispens, T., Verploegen, S. A. B. W., van der Palen‐Merkus, T., Stapel, S. O., Workman, L. J., James, H. R., van Berkel, P. H. C., van de Winkel, J. G. J., Platts‐Mills, T. A. E., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1912 · Cited by 128
Engineering Aggregation-Resistant Antibodies
Perchiacca, J. M., & Tessier, P. M. (2012) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-062011-081052 · Cited by 128
Cation exchange–HPLC and mass spectrometry reveal C-terminal amidation of an IgG1 heavy chain
Johnson, K. A., Paisley-Flango, K., Tangarone, B. S., Porter, T. J., & Rouse, J. C. (2006) · Analytical Biochemistry · doi:10.1016/j.ab.2006.10.012 · Cited by 127
Liu, H., Gaza‐Bulseco, G., & Sun, J. (2006) · Journal of Chromatography B · doi:10.1016/j.jchromb.2006.03.053 · Cited by 127
Self-citationMoorhouse, K. G., Nashabeh, W., Deveney, J., Bjork, N., Mulkerrin, M. G., & Ryskamp, T. (1997) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(97)00178-7 · Cited by 125
Increased serum clearance of oligomannose species present on a human IgG1 molecule
Alessandri, L., Ouellette, D., Acquah, A., Rieser, M., LeBlond, D. J., Saltarelli, M. J., Radziejewski, C. H., Fujimori, T., & Correia, I. (2012) · mAbs · doi:10.4161/mabs.20450 · Cited by 125
Glycation during storage and administration of monoclonal antibody formulations
FISCHER, S., Hoernschemeyer, J., & MAHLER, H. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.04.021 · Cited by 124
Human antibody Fc deamidation in vivo
Liu, D., Enk, J. Z.-V., & Flynn, G. C. (2009) · Biologicals · doi:10.1016/j.biologicals.2009.06.001 · Cited by 124
Self-citationProtein Particulate Detection Issues in Biotherapeutics Development—Current Status
Das, T. K. (2012) · AAPS PharmSciTech · doi:10.1208/s12249-012-9793-4 · Cited by 124
Arosio, P., Rima, S., & Morbidelli, M. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0885-3 · Cited by 123
The effect of Fc glycan forms on human IgG2 antibody clearance in humans
Chen, X., Liu, D., & Flynn, G. C. (2008) · Glycobiology · doi:10.1093/glycob/cwn120 · Cited by 123
Self-citationYadav, S., Sreedhara, A., Kanai, S., Liu, J., Lien, S., Lowman, H. B., Kalonia, D. S., & Shire, S. J. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0410-0 · Cited by 122
Inhibition of Agitation‐Induced Aggregation of an IgG‐Antibody by Hydroxypropyl‐β‐Cyclodextrin
Serno, T., Carpenter, J. F., Randolph, T. W., & Winter, G. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21931 · Cited by 120
Characterization of antibody aggregation: Role of buried, unpaired cysteines in particle formation
Brych, S. R., Gokarn, Y. R., Hultgen, H., Stevenson, R., Rajan, R. S., & Matsumura, M. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21868 · Cited by 119
Gadgil, H. S., Bondarenko, P. V., Pipes, G. D., Dillon, T. M., Banks, D. D., Abel, J., Kleemann, G. R., & Treuheit, M. J. (2006) · Analytical Biochemistry · doi:10.1016/j.ab.2006.05.037 · Cited by 118
Kamoda, S., Ishikawa, R., & Kakehi, K. (2006) · Journal of Chromatography A · doi:10.1016/j.chroma.2006.08.028 · Cited by 115
Ghirlando, R., Lund, J., Goodall, M. D., & Jefferis, R. (1999) · Immunology Letters · doi:10.1016/s0165-2478(99)00029-2 · Cited by 115
Esfandiary, R., Parupudi, A., Casas‐Finet, J. R., Gadre, D., & Sathish, H. A. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24237 · Cited by 115
Nichols, P., Li, L., Kumar, S., Buck, P. M., Singh, S. K., Goswami, S., Balthazor, B., Conley, T. R., Sek, D., & Allen, M. J. (2015) · mAbs · doi:10.4161/19420862.2014.985504 · Cited by 115
Unveiling a Glycation Hot Spot in a Recombinant Humanized Monoclonal Antibody
Boyan, Z., Yang, Y., Yuk, I. H. Y., Pai, R., McKay, P., Eigenbrot, C. W., Dennis, M. S., Katta, V., & Francissen, K. (2008) · Analytical Chemistry · doi:10.1021/ac701810q · Cited by 113
Tous, G. I., Wei, Z., Feng, J., Bilbulian, S., Bowen, S., Smith, J., Strouse, R., McGeehan, P., Casas‐Finet, J. R., & Schenerman, M. A. (2005) · Analytical Chemistry · doi:10.1021/ac0500582 · Cited by 113
Molecular engineering of antibodies for therapeutic and diagnostic purposes
Ducancel, F., & Muller, B. H. (2012) · mAbs · doi:10.4161/mabs.20776 · Cited by 113
Developability studies before initiation of process development
Yang, X., Xu, W., Schussler, S. D., Benchaar, S. A., Mengisen, S., Antochshuk, V., Cheung, J. K., Mann, L., Babadjanova, Z., Rowand, J. L., et al. (2013) · mAbs · doi:10.4161/mabs.25269 · Cited by 113
Self-citationWang, S., Zhang, N., Hu, T., Dai, W., Feng, X., Zhang, X., & Qian, F. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00643 · Cited by 113
Chu, G. C., Chelius, D., Xiao, G., et al. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9241-4 · Cited by 111
Rehder, D. S., Chelius, D., McAuley, A., Dillon, T. M., Xiao, G., Crouse-Zeineddini, J., Vardanyan, L., Perico, N., Mukku, V., Brems, D. N., et al. (2008) · Biochemistry · doi:10.1021/bi7018223 · Cited by 110
Coarse-Grained Modeling of the Self-Association of Therapeutic Monoclonal Antibodies
Chaudhri, A., Zarraga, I. E., Kamerzell, T. J., Brandt, J. P., Patapoff, T. W., Shire, S. J., & Voth, G. A. (2012) · The Journal of Physical Chemistry B · doi:10.1021/jp301140u · Cited by 110
Correlation between the Osmotic Second Virial Coefficient and the Solubility of Proteins
Ruppert, S., Sandler, S. I., & Lenhoff, A. M. (2001) · Biotechnology Progress · doi:10.1021/bp0001314 · Cited by 110
Liu, M., Zhang, Z., Cheetham, J., Ren, D., & Zhou, Z. S. (2014) · Analytical Chemistry · doi:10.1021/ac500334k · Cited by 110
Mo, J., Yan, Q., So, C., Soden, T., Lewis, M. J., & Hu, P. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b01958 · Cited by 110
Aggregation risk prediction for antibodies and its application to biotherapeutic development
Obrezanova, O., Arnell, A., de la Cuesta, R. G., Berthelot, M. E., Gallagher, T. R., Zurdo, J., & Stallwood, Y. (2015) · mAbs · doi:10.1080/19420862.2015.1007828 · Cited by 107
Characterization of trisulfide modification in antibodies
Gu, S., Wen, D., Weinreb, P. H., Sun, Y., Zhang, L., Foley, S. F., Kshirsagar, R., Evans, D. R., Mi, S., Meier, W., et al. (2010) · Analytical Biochemistry · doi:10.1016/j.ab.2010.01.019 · Cited by 107
Farnan, D., & Moreno, G. T. (2009) · Analytical Chemistry · doi:10.1021/ac901408j · Cited by 106
The LC/MS Analysis of Glycation of IGG Molecules in Sucrose Containing Formulations
Gadgil, H. S., Bondarenko, P. V., Pipes, G. D., Rehder, D., McAuley, A., Perico, N., Dillon, T., Ricci, M. S., & Treuheit, M. J. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20966 · Cited by 106
Bumbaca, D., Wong, A., Drake, E. A., Reyes, A. E., Lin, B. C., Stéphan, J.-P., Desnoyers, L., Shen, B., & Dennis, M. S. (2011) · mAbs · doi:10.4161/mabs.3.4.15786 · Cited by 105
Goyon, A., D’Atri, V., Colas, O., Fekete, S., Beck, A., & Guillarme, D. (2017) · Journal of Chromatography B · doi:10.1016/j.jchromb.2017.09.027 · Cited by 105
Self-citationEvaluating Immunogenicity Risk Due to Host Cell Protein Impurities in Antibody-Based Biotherapeutics
Jawa, V., Joubert, M. K., Zhang, Q., Deshpande, M., Hapuarachchi, S., Hall, M. P., & Flynn, G. C. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9948-4 · Cited by 104
Stoll, D., Harmes, D., Danforth, J., Wagner, E., Guillarme, D., Fekete, S., & Beck, A. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b01578 · Cited by 103
Self-citationColoma, M. J., Trinh, R. K., Martinez, A. R., & Morrison, S. L. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.4.2162 · Cited by 103
Courtois, F., Agrawal, N. J., Lauer, T. M., & Trout, B. L. (2015) · mAbs · doi:10.1080/19420862.2015.1112477 · Cited by 101
D’Atri, V., Fekete, S., Beck, A., Lauber, M. A., & Guillarme, D. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.6b04726 · Cited by 101
Self-citationMoon, Y., Curtis, R., Anderson, C. O., et al. (2000) · Journal of Solution Chemistry · doi:10.1023/a:1005112927213 · Cited by 100
He, Y., Isele, C., Hou, W., & Ruesch, M. N. (2011) · Journal of Separation Science · doi:10.1002/jssc.201000719 · Cited by 100
Kaschak, T., Boyd, D., Lu, F., Derfus, G. E., Kluck, B., Nogal, B., Emery, C., Summers, C., Zheng, K., Bayer, R. J., et al. (2011) · mAbs · doi:10.4161/mabs.3.6.17959 · Cited by 100
Arora, J., Hu, Y., Esfandiary, R., Sathish, H. A., Bishop, S. M., Joshi, S. B., Middaugh, C. R., Volkin, D. B., & Weis, D. D. (2016) · mAbs · doi:10.1080/19420862.2016.1222342 · Cited by 100
Toward aggregation-resistant antibodies by design
Lee, C. C., Perchiacca, J. M., & Tessier, P. M. (2013) · Trends in biotechnology · doi:10.1016/j.tibtech.2013.07.002 · Cited by 99
Zhang, A., Hu, P., MacGregor, P. A., Xue, Y., Fan, H., Suchecki, P., Olszewski, L., & Liu, A. (2014) · Analytical Chemistry · doi:10.1021/ac404130a · Cited by 98
Gahoual, R., Busnel, J., Beck, A., François, Y., & Leize‐Wagner, E. (2014) · Analytical Chemistry · doi:10.1021/ac502378e · Cited by 97
Self-citationStructural effect of deglycosylation and methionine oxidation on a recombinant monoclonal antibody
Liu, H., Gaza‐Bulseco, G., Tao, X., & Chumsae, C. M. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.07.012 · Cited by 96
Self-citationEffect of Polysorbate 80 Quality on Photostability of a Monoclonal Antibody
Singh, S. R., Zhang, J., O’Dell, C., Hsieh, M.-C., Goldstein, J., Liu, J., & Srivastava, R. (2012) · AAPS PharmSciTech · doi:10.1208/s12249-012-9759-6 · Cited by 96
Alvarez, M., Tremintin, G., Wang, J. P., Eng, M., Kao, Y., Jeong, J., Ling, V. T., & Borisov, O. V. (2011) · Analytical Biochemistry · doi:10.1016/j.ab.2011.07.033 · Cited by 95
Miller, A. K., Hambly, D. M., Kerwin, B. A., Treuheit, M. J., & Gadgil, H. S. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22504 · Cited by 95
Santora, L. C., Krull, I. S., & Grant, K. (1999) · Analytical Biochemistry · doi:10.1006/abio.1999.4275 · Cited by 95
Fragmentation of a Recombinant Monoclonal Antibody at Various pH
Gaza‐Bulseco, G., & Liu, H. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9606-3 · Cited by 95
Self-citationEffect of protein structure on deamidation rate in the Fc fragment of an IgG1 monoclonal antibody
Sinha, S., Zhang, L., Duan, S., Williams, T. D., Vlasak, J., Ionescu, R. M., & Topp, E. M. (2009) · Protein Science · doi:10.1002/pro.173 · Cited by 95
Li, Y., Polozova, A., Gruia, F., & Feng, J. (2014) · Analytical Chemistry · doi:10.1021/ac404218t · Cited by 93
Bults, P., Bischoff, R., Bakker, H., Gietema, J. A., & van de Merbel, N. C. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b04276 · Cited by 93
Periat, A., Fekete, S., Cusumano, A., Veuthey, J., Beck, A., Lauber, M. A., & Guillarme, D. (2016) · Journal of Chromatography A · doi:10.1016/j.chroma.2016.04.056 · Cited by 93
Self-citationGibson, T. J., McCarty, K. L., McFadyen, I. J., Cash, E., Dalmonte, P., Hinds, K. D., Dinerman, A. A., Alvarez, J. C., & Volkin, D. B. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22350 · Cited by 92
Jacobs, S., Wu, S., Feng, Y., Bethea, D., & O’Neil, K. T. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-0007-z · Cited by 92
Banks, D. D., Hambly, D. M., Scavezze, J. L., Siska, C. C., Stackhouse, N., & Gadgil, H. S. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21749 · Cited by 92
Millward, T. A., Heitzmann, M., Bill, K., Längle, U., Schumacher, P., & Forrer, K. (2007) · Biologicals · doi:10.1016/j.biologicals.2007.05.003 · Cited by 91
Dillon, T. M., Bondarenko, P. V., & Ricci, M. S. (2004) · Journal of Chromatography A · doi:10.1016/j.chroma.2004.08.058 · Cited by 91
Kelly, R. L., Sun, T., Jain, T. S., Caffry, I., Yu, Y., Cao, Y., Lynaugh, H., Brown, M. E., Vásquez, M., Wittrup, K. D., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1043503 · Cited by 90
Self-citationGhazvini, S., Kalonia, C. K., Volkin, D. B., & Dhar, P. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.02.027 · Cited by 90
C‐terminal lysine processing of human immunoglobulin G2 heavy chain in vivo
Cai, B., Pan, H., & Flynn, G. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.22933 · Cited by 89
Stoll, D. R., Danforth, J., Zhang, K., & Beck, A. (2016) · Journal of Chromatography B · doi:10.1016/j.jchromb.2016.05.029 · Cited by 89
Self-citationRates and impact of human antibody glycation in vivo
Goetze, A. M., Liu, D., Arroll, T., Chu, L., & Flynn, G. C. (2011) · Glycobiology · doi:10.1093/glycob/cwr141 · Cited by 88
Self-citationSorensen, M., Harmes, D. C., Stoll, D. R., Staples, G. O., Fekete, S., Guillarme, D., & Beck, A. (2016) · mAbs · doi:10.1080/19420862.2016.1203497 · Cited by 88
Self-citationBanks, D. D., Gadgil, H. S., Pipes, G. D., Bondarenko, P. V., Hobbs, V., Scavezze, J. L., Kim, J., Jiang, X., Mukku, V. R., & Dillon, T. M. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21014 · Cited by 87
Immunogenicity screening in protein drug development
Walle, I. V., Gansemans, Y., Parren, P. W. H. I., Stas, P., & Lasters, I. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.3.405 · Cited by 87
Cited by
Predicting antibody developability profiles through early stage discovery screening
Bailly, M., Mieczkowski, C., Juan, V., Metwally, E., Tomazela, D., Baker, J., Uchida, M., Kofman, E., Raoufi, F., Motlagh, S., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1743053 · Cited by 228
Self-citationLai, P.-K., Gallegos, A., Mody, N., Sathish, H. A., & Trout, B. L. (2022) · mAbs · doi:10.1080/19420862.2022.2026208 · Cited by 103
Sawyer, W. S., Srikumar, N., Carver, J., Chu, P. Y., Shen, A., Xu, A., Williams, A. J., Spiess, C., Wu, C., Liu, Y., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1917383117 · Cited by 55
Bashour, H., Smorodina, E., Pariset, M., Zhong, J., Akbar, R., Chernigovskaya, M., Lê Quý, K., Snapkow, I., Rawat, P., Krawczyk, K., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06561-3 · Cited by 32
The therapeutic antibody profiler for computational developability assessment
Raybould, M. I. J., & Deane, C. M. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1450-1_5 · Cited by 25
Metadata
- Authors
- Xu, Y., Wang, D., Mason, B., Rossomando, T., Li, N., Liu, D., Cheung, J. K., Xu, W., Raghava, S., Katiyar, A., Nowak, C., Xiang, T., Dong, D. D., Sun, J., Beck, A., & Liu, H.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2018-12-17
- Volume
- 11
- Issue
- 2
- Pages
- 239-264
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W2904971004
- Cited by
- 264
- References
- 322
- FWCI
- 7.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.